This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iljin, K. Articles by Kallioniemi, O. Search for Related Content PubMed PubMed Citation Articles by Iljin, K. Articles by Kallioniemi, O.

TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming

¹ Medical Biotechnology, VTT Technical Research Centre of Finland and University of Turku, Turku, Finland; ² Department of Cancer Prevention, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway; and ³ Department of Urology, Radboud University Nijmegen Medical Center, the Netherlands

Requests for reprints: Olli Kallioniemi, Medical Biotechnology Centre, VTT Technical Research Centre of Finland and University of Turku, Turku, Finland. Phone: 358-2478-8602; Fax: 358-2478-8601; E-mail: Olli.Kallioniemi{at}vtt.fi.

Translocations fusing the strong androgen-responsive gene, TMPRSS2, with ERG or other oncogenic ETS factors may facilitate prostate cancer development. Here, we studied 18 advanced prostate cancers for ETS factor alterations, using reverse transcription-PCR and DNA and RNA array technologies, and identified putative ERG downstream gene targets from the microarray data of 410 prostate samples. Out of the 27 ETS factors, ERG was most frequently overexpressed. Seven cases showed TMPRSS2:ERG gene fusions, whereas the TMPRSS2:ETV4 fusion was seen in one case. In five out of six tumors with high ERG expression, array-CGH analysis revealed interstitial 2.8 Mb deletions between the TMPRSS2 and ERG loci, or smaller, unbalanced rearrangements. In silico analysis of the ERG gene coexpression patterns revealed an association with high expression of the histone deacetylase 1 gene, and low expression of its target genes. Furthermore, we observed increased expression of WNT-associated pathways and down-regulation of tumor necrosis factor and cell death pathways. In summary, our data indicate that the TMPRSS2:ERG translocation is common in advanced prostate cancer and occurs by virtue of unbalanced genomic rearrangements. Activation of ERG by fusion with TMPRSS2 may lead to epigenetic reprogramming, WNT signaling, and down-regulation of cell death pathways, implicating ERG in several hallmarks of cancer with potential therapeutic importance. (Cancer Res 2006; 66(21): 10242-6)

This article has been cited by other articles:

				J. Arts, P. King, A. Marien, W. Floren, A. Belien, L. Janssen, I. Pilatte, B. Roux, L. Decrane, R. Gilissen, et al. JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity Clin. Cancer Res., November 15, 2009; 15(22): 6841 - 6851. [Abstract] [Full Text] [PDF]

				K. Iljin, K. Ketola, P. Vainio, P. Halonen, P. Kohonen, V. Fey, R. C. Grafstrom, M. Perala, and O. Kallioniemi High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth Clin. Cancer Res., October 1, 2009; 15(19): 6070 - 6078. [Abstract] [Full Text] [PDF]

				A. Gopalan, M. A. Leversha, J. M. Satagopan, Q. Zhou, H. A. Al-Ahmadie, S. W. Fine, J. A. Eastham, P. T. Scardino, H. I. Scher, S. K. Tickoo, et al. TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy Cancer Res., February 15, 2009; 69(4): 1400 - 1406. [Abstract] [Full Text] [PDF]

				Q. Lu, E. Nunez, C. Lin, K. Christensen, T. Downs, D. A. Carson, J. Wang-Rodriguez, and Y.-T. Liu A sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants Nucleic Acids Res., November 1, 2008; 36(20): e130 - e130. [Abstract] [Full Text] [PDF]

				B. Han, R. Mehra, S. M. Dhanasekaran, J. Yu, A. Menon, R. J. Lonigro, X. Wang, Y. Gong, L. Wang, S. Shankar, et al. A Fluorescence In situ Hybridization Screen for E26 Transformation-Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer Cancer Res., September 15, 2008; 68(18): 7629 - 7637. [Abstract] [Full Text] [PDF]

				G Attard, J E Ang, D Olmos, and J S de Bono Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development J. Clin. Pathol., August 1, 2008; 61(8): 891 - 896. [Abstract] [Full Text] [PDF]

				J.-M. Mosquera, S. Perner, E. M. Genega, M. Sanda, M. D. Hofer, K. D. Mertz, P. L. Paris, J. Simko, T. A. Bismar, G. Ayala, et al. Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications Clin. Cancer Res., June 1, 2008; 14(11): 3380 - 3385. [Abstract] [Full Text] [PDF]

				O. R. Saramaki, A. E. Harjula, P. M. Martikainen, R. L. Vessella, T. L.J. Tammela, and T. Visakorpi TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis Clin. Cancer Res., June 1, 2008; 14(11): 3395 - 3400. [Abstract] [Full Text] [PDF]

				R. Mehra, S. A. Tomlins, J. Yu, X. Cao, L. Wang, A. Menon, M. A. Rubin, K. J. Pienta, R. B. Shah, and A. M. Chinnaiyan Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer Cancer Res., May 15, 2008; 68(10): 3584 - 3590. [Abstract] [Full Text] [PDF]

				O. Klezovitch, M. Risk, I. Coleman, J. M. Lucas, M. Null, L. D. True, P. S. Nelson, and V. Vasioukhin A causal role for ERG in neoplastic transformation of prostate epithelium PNAS, February 12, 2008; 105(6): 2105 - 2110. [Abstract] [Full Text] [PDF]

				B. E. Helgeson, S. A. Tomlins, N. Shah, B. Laxman, Q. Cao, J. R. Prensner, X. Cao, N. Singla, J. E. Montie, S. Varambally, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer Cancer Res., January 1, 2008; 68(1): 73 - 80. [Abstract] [Full Text] [PDF]

				S. Jhavar, A. Reid, J. Clark, Z. Kote-Jarai, T. Christmas, A. Thompson, C. Woodhouse, C. Ogden, C. Fisher, C. Corbishley, et al. Detection of TMPRSS2-ERG Translocations in Human Prostate Cancer by Expression Profiling Using GeneChip Human Exon 1.0 ST Arrays J. Mol. Diagn., January 1, 2008; 10(1): 50 - 57. [Abstract] [Full Text] [PDF]

				F. Demichelis and M. A Rubin TMPRSS2-ETS fusion prostate cancer: biological and clinical implications J. Clin. Pathol., November 1, 2007; 60(11): 1185 - 1186. [Full Text] [PDF]

				A. B Rajput, M. A Miller, A. De Luca, N. Boyd, S. Leung, A. Hurtado-Coll, L. Fazli, E. C Jones, J. B Palmer, M. E Gleave, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers J. Clin. Pathol., November 1, 2007; 60(11): 1238 - 1243. [Abstract] [Full Text] [PDF]